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Oligopeptide repeats appear in many 
proteins that undergo conformational 
conversions to form amyloid, including the 
mammalian prion protein PrP and the yeast 
prion protein Sup35.  While the repeats in PrP 
have been studied more exhaustively, 
interpretation of these studies is confounded by 
the fact that many details of the PrP prion 
conformational conversion are not well 
understood.  On the other hand, there is now a 
relatively good understanding of the factors 
that guide the conformational conversion of the 
Sup35 prion protein.  In order to provide a 
general model for studying the role of 
oligopeptide repeats in prion conformational 
conversion and amyloid formation, we have 
substituted various numbers of the PrP 
octarepeats for the endogenous Sup35 repeats.  
The resulting chimeric proteins can adopt the 
[PSI+] prion state in yeast, and the stability of 
the prion state depends on the number of 
repeats.  In vitro, these chimeric proteins form 
amyloid fibers, with more repeats leading to 
shorter lag phases and faster assembly rates.  
Both pH and the presence of metal ions 
modulate assembly kinetics of the chimeric 
proteins, and the extent of modulation is highly 
sensitive to the number of PrP repeats.  This 
work offers new insight into the properties of 
the PrP octarepeats in amyloid assembly and 
prion formation.  It also reveals new features of 
the yeast prion protein, and provides a level of 
control over yeast prion assembly that will be 
useful for future structural studies and for 
creating amyloid-based biomaterials. 
 
Prions were originally recognized as the 
causative agent of several mammalian 
neurodegenerative disorders, including scrapie in 
sheep, bovine spongiform encephalopathy (mad 
cow disease) in cattle, and Creutzfeldt-Jakob 
disease (CJD) in humans (1).  According to the 
prion hypothesis, these maladies are due to a 
conformational conversion of the normal cellular 
prion protein (PrPC) into an abnormal pathological 
isoform (PrPSc), a portion of which becomes 
highly resistant to proteinase-K digestion.  Once 
prion formation is initiated (i.e. spontaneous 
conversion of cellular PrPC to PrPSc to generate 
infectivity), the PrPSc conformers can self-replicate 
by templating the conformational conversion of 
other PrPC molecules (1).  Several prion-like 
proteins identified in yeast can also perpetuate 
their conformational state through a protein-based 
templating mechanism. Instead of causing fatal 
diseases, however, the yeast prions are sometimes 
beneficial, and can act as protein-only elements of 
inheritance (2).  For instance, the yeast prion 
phenotype [PSI+] is the result of the self-
replicating conformational conversion of the 
protein Sup35, a translation termination factor.  In 
its prion conformation, Sup35 is sequestered from 
its normal function, resulting in increased read-
through of nonsense codons.  This read-through 
can ultimately confer a wide spectrum of heritable 
new phenotypes (3-5).  In vitro the Sup35 prions 
can form amyloid fibers in a template-based 
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reaction that is thought to parallel in vivo prion 
conformational conversion and is reminiscent of 
the fiber formation of a wide range of 
amyloidogenic proteins (2). 
The mammalian PrP and Sup35 share several 
similar structural characteristics, including a well-
folded C-terminal core and a natively unfolded N-
terminus.  The N-termini of both proteins contain 
oligopeptide repeats  that influence their 
conformational conversion to the prion state (6-10).  
The N-terminus of wild-type human PrPC contains 
four perfect copies of a highly conserved 
octarepeat sequence (11), PHGGGWGQ, and one 
imperfect copy, PQGGGTWGQ.  Expansion of 
the octarepeat region, ranging from one to nine 
extra copies, has been found in several types of 
familial CJD and is associated with an earlier 
onset of pathology (12,13).  When transgenic mice 
that express repeat-free PrP are infected by scrapie 
extracts or by PrP aggregates, they show a slower 
progression of disease (9,14) and exhibit different 
histopathological characteristics than mice with 
the wild-type protein (15).  In vitro, expansion of 
the octarepeat region increases the spontaneous 
conversion rate of PrPC to a protease-resistant 
conformation (16).  Likewise, when the octarepeat 
region is fused to a GST (glutathione S-transferase) 
protein, it accelerates protein self-association and 
allows selective binding of PrPSc from brain 
extracts (17).  Sup35 has five imperfect copies of 
PQGGYQQYN. Reducing the number of repeats 
lowers the frequency of spontaneous prion 
induction (7,18).  Furthermore, the prion state 
associated with this variant is unstable and 
frequently spontaneously converts back to the non-
prion state, [psi-] (7).  Sup35 with an expanded 
number of repeats, however, induces a new and 
stable prion state much more frequently than wild-
type Sup35 (7).    
Oligopeptide repeats of various lengths and 
compositions appear in several other amyloid-
forming proteins in addition to prion proteins.  The 
huntingtin protein associated with Huntington’s 
disease contains a perfect polyglutamine repeat, 
and expansion of this repeat region results in early 
onset of the disease and an increase in the rate of 
in vitro amyloid formation (19,20).  α-Synuclein, 
a protein that plays a role in Parkinson disease and 
assembles into amyloid fibers in vitro, contains 
seven copies of a less defined repeat, 
XKTKEGVXXXX (21).  The major and minor 
components of the E. coli curli protein each 
consist of five 16-18mer repeats, which are 
required for the formation of curli amyloid fibers 
and are involved in cell aggregation, biofilm 
formation and surface adhesion (22,23).  Although 
oligopeptide repeats are clearly a crucial feature of 
these amyloid-forming proteins, the exact 
structural and functional role of these repeats 
remains unclear.   
Compared to these other oligopeptide repeats, 
the biophysical properties of the PrP octarepeats 
are well characterized.  The octarepeat of PrP can 
selectively bind Cu(II) ions (24), and the histidine 
residues in the octarepeats act as the primary 
anchor point for Cu(II)-binding (24).  Structurally, 
Cu(II) binding can induce a conformational 
conversion of PrPC into protease-resistant species 
(10) and the efficiency of this conversion depends 
on the number of octarepeats (17).  Cu(II) ions 
combined with nicotinamide adenine dinucleotide 
phosphate (NADPH) can even induce spontaneous 
conformational change and aggregation of 
HuPrP(23-98), a variant that only contains the 
octarepeat region of human PrP (25). Functionally, 
Cu(II) binding to the octarepeats induces PrPC 
endocytosis in neuronal cells, indicating a role for 
PrPC in Cu(II) sensing, uptake and/or transport 
(26).  Superoxide dismutase (SOD)-like activities 
have also been reported for the Cu(II)-bound PrPC, 
suggesting a neuronal function of PrPC as an anti-
oxidant (27-29), although that is still a subject of 
debate (30).  Treatment of scrapie-infected mice 
with Cu(II) chelator D-(-)-penicillamine (D-PEN) 
delays the onset of prion disease in mice (31). 
While the biophysical properties of the PrP 
repeats have been studied extensively, the role of 
the repeats in prion conformational conversion is 
not well understood, particularly because of the 
lack of knowledge on many details of PrP prion 
formation.  One the other hand, the factors that 
guide prion conformational conversion have been 
best defined for Sup35.  These factors include 
molecular chaperones that influence 
conformational conversion (32-35), as well as 
specific sequence elements that control the 
maintenance and nucleation of the prion 
conformation and govern the formation of distinct 
prions strains and the existence of prion species 
barriers (36-40).  To provide a new model for 
studying prion conformational conversion and to 
better understand the role of the oligopeptide 
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repeats in amyloid formation, we explored the role 
of the PrP octarepeats in the context of the yeast 
prion protein Sup35.  We created chimeric 
proteins in which different numbers of hamster 
PrP repeats were substituted for the endogenous 
Sup35 repeats.  Facilitated by the powerful genetic 
and biophysical techniques developed for yeast 
prions, we were able to characterize how the PrP 
octarepeats influence the conformational 
conversion and amyloid formation of these 
chimeric prion proteins both in vivo and in vitro.   
We find that increasing the number of PrP 
repeats in the chimeric proteins increases the 
spontaneous appearance of the [PSI+] phenotype 
in vivo and accelerates amyloid formation in vitro.  
Conformational conversion and amyloid formation 
by the chimeras are modulated by both pH and the 
presence of metal ions. Further, the manner in 
which these factors modulate conversion is highly 
sensitive to the number of PrP repeats.  Our work 
offers new insight into the role of the PrP 
octarepeats in amyloid formation and prion 
formation, with implications for prion structure. It 
also allows us to control protein assembly by 
simply altering environmental conditions. This 
control will be useful for further functional and 
structural work and could provide a practical 
means of controlling assembly for biomaterial and 
biotechnology applications.  
 
 
EXPERIMENTAL PROCEDURES  
 
Plasmid construction and gene integration: 
A Sup35 integrative vector was constructed using 
pRS306 (41).  A fragment spanning from 1360 
nucleotides upstream of Sup35 through a 5’ region 
of Sup35 with a BspE1 site after the first Sup35 
repeat was amplified (PCR primers 5’-
CGACGGTATCGATAAGCTTG-3’ and 5’-
GATAGCCTCTAGATTGGTATCCGGAATAAC 
CTTG-3’) and ligated into pRS306 between ClaI 
and XbaI sites.  A second fragment spanning from 
Sup35 downstream from the repeats with an EagI 
site just after the repeats to 800 nucleotides 
downstream from Sup35 was amplified (PCR 
primers 5’-CAGCAATCTAGACCACAAGGC 
GGCCGTGGAAATTAC-3’ and 5’-CGAATTGG 
AGCTCTTACTCG-3’) and ligated into the 
plasmid between XbaI and SacI sites.  This 
plasmid was sequenced through the entire Sup35 
region, and was named pRS306Sup35R1. 
The first two PrP repeats were added to 
pRS306Sup35R1 by annealing two 
complementary oligonucleotides and inserting 
them between the BspE1 and EagI sites.  To insure 
high purity of these lengthy oligos, they were 
ordered PAGE purified and phosphorylated from 
Research Genetics (oligo sequences 5’-CCGGAT 
ATCCACAAGGTGGAGGTACTTGGGGTCAA
CCCCATGGAGGTGGTTGGGGTCAACCACA
AGGC-3’ and 5’-GGCCGCCTTGTGGTTGAC 
CCCAACCACCTCCGGGTTGACCCCAAGTAC
CTCCACCTTGTGGATAT-3’), and contained a 
BstXI site.  The resulting plasmid was named 
pRS306Sup35R1+2.  Subsequent repeats were 
added by inserting annealed oligos encoding three 
PrP repeats in the BstXI site (oligo sequences 5’-
GAGGTTGGGGTCAACCCCATGGAGGAGGT
TGGGGTCAACCCCATGGAGGTGGTTGGGG
TCAACCCCATGGAG-3’ and 5’-ATGGGGTT 
GACCCCAACCACCTCCATGGGGTTGACCCC
AACCTCCTCCATGGGGTTGACCCCAACCTC
CTCC-3’).  The addition of one copy of these 
annealed oligos created pRS306Sup35R1+5.  The 
oligos contained two BstXI sites, so digestion with 
BstXI and self-ligation created pRS306-
Sup35R1+4, while digestion with BstXI and 
insertion of another copy of the annealed oligos 
created pRS306Sup35R1+7.  In a similar manner, 
pRS306Sup35R1+6 and pRS306Sup35R1+8 were 
created.  All of these plasmids were sequenced 
through the repeat region to confirm accuracy. 
The plasmids for the R1+8H1Q chimera were 
created by the same method, inserting oligos 
encoding PrP repeats in which the histidines were 
changed to glutamines into pRS306Sup35R1+2 
(oligo sequences 5’-GAGGTTGGGGTCAACCC 
CAAGGAGGAGGTTGGGGTCAACCCCAAGG
AGGTGGTTGGGGTCAACCCCAAGGAG-3’ 
and 5’-TTGGGGTTGACCCCAACCACCTCCTT 
GGGGTTGACCCCAACCTCCTCCTTGGGGTT
GACCCCAACCTCCTCC-3’).  The plasmids 
pRS306Sup35R1+8H1Q was created in this 
manner and sequenced through the repeat region.  
Note that these plasmids still contained the one 
histidine that was present in the repeats in 
pRS306Sup35R1+2. 
Bacterial expression constructs for R1+4, 
R1+8 and R1+8H1Q were created by excising the 
repeat region from the corresponding integration 
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constructs with BstEII and MscI and ligating it into 
these sites in the expression construct 
pJC25NMstop (42).  These constructs were named 
pJC25R1+4stop, pJC25R1+8stop and pJC25-
R1+8H1Q. These plasmids were sequenced 
through the repeat region to confirm accuracy. 
Gene integration and replacement: The 
integration constructs were linearized with MluI 
and transformed into a [psi-] 74-D694 (genotype: 
ade1-14(UGA), trp1-289(UAG), his3∆-200, ura3-
52, leu2-3,112) strain.  Transformants were 
selected on uracil-deficient medium (SD-Ura), and 
recombinant excision events were selected on 
medium containing 5-fluoro-orotic acid.  Strains in 
which the wild-type Sup35 gene had been replaced 
by the mutant copy were identified by PCR of a 
portion of the genomic Sup35 gene.  The repeat 
region of the Sup35 gene was sequenced to 
confirm accuracy. 
Spontaneous appearance of [PSI+] in R1+X 
yeast strains: All R1+X strains were grown on 
YPD plates, and then inoculated in liquid YPD.  
After overnight growth, the cells were plated on 
ADE- at 0.7X106, 1.4X106 and 6X106 cells/plate. 
After seven days of incubation, colonies were 
counted. 
Protein purification: Crude preparations of 
proteins were purified as previously described (43).  
Mass spectrometry analysis yielded the following 
masses: R1+4 was 27171.1 Da (calculated value is 
27170.1 Da), R1+8 was 30277.6 Da (calculated 
value is 30277.3Da), and R1+8H1Q was 30222.9 
Da (calculated value is 30223.3 Da).  Protein 
concentrations were determined using the 
absorbance at 280 nm with molar extinction 
coefficients calculated as 25600 (NM), 39400 
(R1+4), 62160 (R1+8), and 62160 (R1+8H1Q). 
Fiber formation: Proteins were dissolved in 
6M guanidine hydrochloride as a stock solution 
and the concentration was determined by the 
absorbance at 280nm.  Solutions for unseeded 
polymerization reactions were prepared by 
dilution of the stock solution into aqueous buffers 
and allowed to assemble at room temperature 
either with our without agitation.  Seeds for seeded 
reactions were prepared by sonicating preformed 
fibers in a VWR Aquasonic 50T water bath 
sonicator, and all seeded reactions contained 2% 
(w/w) of the seeds. 
The buffers for the tests at different pH’s are: 
pH 7.2, 20 mM MOPS with 100 mM sodium 
chloride; pH 6.2, 5 mM potassium phosphate with 
50 mM sodium sulfate; pH 4.9, 3.9 and 2.9, 5 mM 
potassium acetate with 50 mM sodium sulfate.   
Cu(II) binding reactions: Lyophilized protein 
was first dissolved in acidified 25 mM NEM, 
300mM NaCl and spin filtered through a 300 kDa 
cutoff membrane. An appropriate volume of 100 
mM CuCl2 in deionized water was added and 
samples were mixed. Then samples were diluted to 
5-20 µM final protein concentration using 30mM 
NEM pH 8.1.  All EPR samples contained 20% 
(v/v) glycerol as a cryoprotectant. 
Electron Spin Resonance Spectroscopy: X-
band spectra (9.43 GHz) were acquired using a 
Bruker ELEXSYS E500 spectrometer and a TE102 
cavity. Measurements were performed at ~115-
125K in a nitrogen vapor using cavity equipped 
with variable temperature control. The total bound 
Cu(II) was quantified by spin integration and 
comparison to accurate standard solutions 
containing Cu(II) in 10mM imidazole at pH 7.4. 
Thioflavin-T binding: Fiber formation was 
monitored by Thioflavin-T (44) in both seeded and 
unseeded reactions (45).  Attenuated Thioflavin T 
(ThT) intensity was observed at acidic pHs and in 
the presence of Cu(II), when SDS assay showed 
the same amount of free monomers left after 
polymerization reactions.  ThT fluorescence 
intensity was baseline subtracted and then 
normalized to the maximum intensity when the 
polymerization reaction reached equilibrium. 
Monitoring fiber formation by SDS solubility: 
At the indicated time points, 20μl of the assembly 
mix was withdrawn and added to SDS-PAGE 
sample buffer.  Samples were run on 12.5% SDS-
PAGE gels and stained with Coomassie Blue G-
250.  The percentage of soluble protein was 
calculated by (gel band intensity at indicated time 
point) divided by (gel band intensity of zero hour 
sample after boiling). 
 
RESULTS 
 
Chimeric Sup35 proteins with PrP repeats 
can support both the prion and non-prion states. 
We first constructed chimeric proteins consisting 
of Sup35 with different numbers of PrP repeats 
substituted for the repeats of Sup35.  Since the 
first repeats of Sup35 and PrP are the least similar 
to each other in sequence, and since the first 
Sup35 repeat is spatially separated from the others, 
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we kept it intact.  The last four full Sup35 repeats 
were replaced with the repeats from hamster PrP: 
one copy of the first hamster PrP imperfect repeat 
(PQGGGTWGQ) followed by varying numbers of 
the perfect hamster PrP repeats (PHGGGWGQ), 
as shown in Fig. 1A.  Since our chimeras 
contained the first repeat (R1) of Sup35 plus two, 
four, five, six, seven, and eight repeats, they were 
named R1+2, R1+4, R1+5, R1+6, R1+7, and 
R1+8. 
We first asked how these chimeric proteins 
affected yeast prion biology in vivo.  Starting with 
[psi-] cells, the wild-type SUP35 gene was 
replaced with a gene encoding R1+2, R1+4, R1+5, 
R1+6, R1+7, or R1+8 by homologous 
recombination.  The strain we employed contains a 
nonsense codon in the ADE1 gene. In [PSI+] cells, 
wherein most of the Sup35 translation termination 
factor is sequestered in prion aggregates, 
ribosomes sometimes read through the stop codon.  
This allows the cells to grow on adenine deficient 
media (SD-Ade) and causes them to form white 
colonies when grown on rich media (YPD) (46,47).  
The [psi-] cells do not grow on SD-Ade, and 
produce red colonies on YPD because of the 
accumulation of a metabolic by-product of adenine 
biosynthesis (46).  Strains in which wild-type 
Sup35 was replaced with R1+2 through R1+8 
substitutions remained [psi-].  
Increasing the number of PrP repeats 
destabilizes both the [psi-] and [PSI+] states. 
When wild-type cells are grown in YPD, they are 
stable in both the [PSI+] and the [psi-] states, and 
the rate of spontaneous conversion between these 
states is very low (7).  To determine the stability 
of the [psi-] state in our mutant strains, we 
observed the spontaneous appearance of [PSI+] by 
streaking [psi-] cells on YPD followed by an SD-
Ade plate.  Wild-type Sup35 [psi-] strains 
produced colonies on SD-Ade medium rarely, 
approximately one per 106 cells/plate.  R1+2, 
R1+4, R1+5, also rarely produced colonies.  In 
contrast, colonies appeared ~10 fold more 
frequently on SD-Ade medium with R1+6 and 
~100 fold more frequently with R1+7 and R1+8 
strains.  The colonies were confirmed as being true 
[PSI+] colonies by taking advantage of the fact 
that cells can be cured of the prion state by 
growing them on media containing guanidine 
hydrochloride.  This produced red colonies that 
could not grow on SD-Ade medium. Thus, repeat 
expansion increased rate of spontaneous 
conversion from the [psi-] to the [PSI+] state.  
Next we examined the spontaneous 
conversion of R1+X [PSI+] strains to [psi-].  To 
create [PSI+] strains of R1+2, R1+4, R1+5, and 
R1+6, large numbers of the [psi-] strains were 
plated on SD-Ade and colonies that grew were 
selected.  All of the [PSI+] strains were confirmed 
by growth and curing in the presence of 5 mM 
Gdn⋅HCl.  Fig. 1B shows the growth of R1+X 
strains in both [psi-] and [PSI+] states on YPD.  
When R1+2, R1+4, R1+5, and R1+6 [PSI+] strains 
were grown on YPD rich medium, the colonies 
appeared white, and red colonies were rarely 
observed, similar to wild-type Sup35 [PSI+] strains.  
Thus, the [PSI+] states of R1+2, R1+4, R1+5, and 
R1+6 were maintained stably.  However, R1+7 
and R1+8 strains frequently converted to [psi-] on 
YPD plates, with the colonies sectoring to red 
around the perimeter. Thus, extra copies of the PrP 
octarepeats destabilize both the prion and non-
prion states. 
Increasing the number of PrP repeats 
dramatically accelerates amyloid formation in 
vitro. Sup35 can be divided into three distinct 
regions, the N-terminus with the oligopeptide 
repeats (amino acids 1-123), a highly charged 
middle region, and the C-terminus (a.a. 254-685), 
which functions as a translation termination factor.  
The N-terminus (N) and the middle region (M) of 
Sup35, often called NM, forms the prion-
determining (PrD) domain.  In vitro assembly of 
NM amyloid fibers recapitulates the induction and 
propagation of yeast prions in vivo (7,39,48,49), 
and transformation of NM fibers into [psi-] yeast 
cells (50) induces the formation of yeast prion 
phenotypes (36,39,48).  To examine the 
amyloidogenic properties of the R1+X proteins, 
we chose to purify the NM domains of wild-type 
Sup35, R1+4 and R1+8.  Amyloid fibers formed 
by the R1+4 and R1+8 chimeras were examined 
by atomic force microscopy (AFM).  They were 
morphologically indistinguishable from those 
formed by wild-type NM (Fig. S1). 
The kinetics of amyloid formation were 
monitored both by a Thioflavin-T (ThT) binding 
assay and by an assay for resistance to 
solublization by SDS (46).  Wild-type NM or 
chimeric NMs were diluted from a 6M Gdn⋅HCl 
stock solution into aqueous buffer and incubated at 
room temperature with agitation, a standard 
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condition that accelerates assembly.  Under these 
conditions, all of the proteins exhibited behavior 
typical of spontaneous, nucleated amyloid 
formation, with an initial lag phase followed by an 
assembly phase (Fig. 2A). However, wild-type 
NM and the chimeras exhibited very different lag 
times.  Both chimeras with PrP repeats showed a 
shorter lag phase than wild-type NM.  Moreover, 
R1+8 exhibited a shorter lag phase than R1+4. 
These experiments were performed many times 
with independent protein preparations. Although 
the absolute lag times varied somewhat from 
experiment to experiment, the differences between 
the behavior of three proteins was extremely 
consistent. This result indicates that the PrP 
octarepeat is more amyloidogenic than the Sup35 
repeat, and that the number of PrP octarepeats can 
greatly alter the intrinsic capacity of the proteins to 
form amyloid. 
To test the effects of the PrP repeats on the 
assembly phase of amyloid formation, seeded 
polymerization reactions were monitored.  Pre-
formed NM fibers seeded fiber formation of wild-
type NM with elimination of the lag phase (46) 
(Fig. 2B).  Wild-type NM fibers also effectively 
seeded fiber formation of R1+4 and R1+8 (2% 
w/w seed, Fig. 2B).  Moreover, all three proteins 
were able to effectively cross seed each other (Fig. 
2B).  In all seeded reactions and regardless of the 
nature of the seeds R1+8 assembled much faster 
than R1+4 and wild-type NM.  These findings 
were confirmed by SDS resistance assay (data not 
shown). Thus, the number of the PrP repeats 
influences both the spontaneous nucleation rate 
and the inherent assembly rate of amyloid 
formation.  But strikingly, the repeats have little 
effect on seeding or cross-seeding capacity. 
Histidine residues in the PrP repeats confer 
pH sensitivity on amyloid formation.  We then 
explored the factors that may affect the 
conformation of the repeat region and thereby the 
process of amyloid formation.  Previous studies 
showed that conformational conversion of 
truncated PrPs free of the repeat region was 
sensitive to pH (51-53) and the remaining histidine 
residues in the truncated PrP were suggested to be 
crucial for this pH sensitivity (54).  To our 
knowledge, the role of histidines in the 
octapepetide repeats has not been well tested. To 
examine the effect of pH on the spontaneous 
assembly of the chimeras, we used quiescent 
reaction conditions, which extend the lag phase.  
Amyloid formation by wild-type NM, R1+4 and 
R1+8 in buffers with different pH’s was monitored 
by both ThT (Fig. 3A) and SDS (Fig. S2) assays.  
The lag phase of wild-type NM was insensitive to 
pH, with similar amyloid formation time courses 
at pH 7.2, 6.2, 4.9, 3.9 and 2.9.  In contrast, 
lowering the pH lengthened the lag phase for both 
R1+4 and R1+8, with the effect especially 
profound for R1+8. The lag phase for R1+8 was 
less than 2 hours at pH 7.2 and 6.2, but it was 
more than 10 hours at pH 4.9 and more than 30 
hours at pH 2.9.  We also investigated the effects 
of pH on seeded assembly (Fig. 3B and Fig. S3).  
The assembly rate of wild-type NM remained 
almost unchanged.  However, the assembly rate of 
R1+4 and R1+8 decreased at lower pH.  Moreover, 
R1+8 was more sensitive to pH changes than 
R1+4, particularly at pH 4.5.   
To directly test whether the histidine residues 
are responsible for the pH dependence of assembly, 
we mutated the histidines in the repeat region of 
R1+8 to glutamines (changing PHGGGWGQ to 
PQGGGWGQ).  Glutamine was chosen since it is 
present in the first imperfect repeat 
(PQGGGTWGQ) in the same location as the 
histidine in the subsequent PHGGGWGQ repeats 
(Fig. 1A).  Due to details of the cloning procedure, 
the histidine was not removed from the second PrP 
repeat.  Therefore, this new chimera contained 
only a single PrP repeat with histidine, and was 
named R1+8H1Q.  The histidine replacement had 
no obvious effect on the function of the protein in 
vivo: R1+8H1Q strains supported both [PSI+] and 
[psi-] states, and the purified NM domain of 
R1+8H1Q formed amyloid fibers in vitro (Fig. 2 
and below).  However, unlike the R1+4 and R1+8 
proteins with histidines in the repeats, both the 
spontaneous nucleation rate and the assembly rate 
for amyloid formation by R1+8H1Q was almost 
unchanged across the entire tested pH range, from 
pH 7.2 to 2.9 (Fig. 3A and 3B).  Thus, the 
histidine residues are the primary source of the pH 
sensitivity of amyloid formation by the R1+4 and 
R1+8 proteins.  
Interplay between Cu(II) and PrP repeats 
shows complex effects on amyloid formation in 
vitro.  It has been extensively shown that the PrP 
repeats can selectively bind Cu(II) ions (24,55-58).  
Therefore, we explored the effect of Cu(II) on the 
conformational conversion and amyloid formation 
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of the chimeras.  First, we investigated the Cu(II)-
binding sites in non-assembled NM and R1+X 
proteins by Electron Paramagnetic Resonance 
(EPR).  EPR has been previously applied to 
determine the molecular features of the Cu(II)-
binding sites in recombinant full-length Syrian 
hamster PrPC (59).  Those results showed that 
Cu(II) coordination depends highly on the relative 
concentration of Cu(II) to PrPC (60).  With excess 
amount of Cu(II), copper fully occupies individual 
repeat units, one Cu(II) per repeat unit, 
coordinating with the His imidazole and two 
deprotonated glycine amides (59,61).  The EPR 
spectra of Cu(II)-bound R1+4 and R1+8 are nearly 
indistinguishable from that of Cu(II)-bound 
recombinant PrPC at full occupancy (60), although 
in R1+8 there may be additional broadening in the 
parallel region (approximately 2700 G – 3100 G; 
Fig. 4).  This broadening is possibly due to Cu(II)-
Cu(II) dipolar interactions.  On average, R1+4 
bound 4-5 equivalents of Cu(II), and R1+8 bound 
up to 10 equivalents.  Wild-type NM and 
R1+8H1Q bind Cu(II) at approximately 2 and 4 
equivalents respectively.  They might bind Cu(II) 
via histidine residues outside the octarepeat region, 
and/or the free amino group at the N-terminus.  
R1+8H1Q retains a single histidine-containing 
repeat, which is also likely responsible for the 
additional Cu(II) binding compared to wild-type 
NM. 
We then investigated the effects of Cu(II) on 
amyloid formation by the R1+X chimeras.  10 
equivalents of Cu(II) were added into NM and 
R1+4 solution, and 20 equivalents were added into 
R1+8 and R1+8H1Q.  As a result, the ratio of 
[Cu(II)]/[single repeat] is constant, eliminating a 
variable that influences Cu(II) coordination 
environment (60).  Formation of amyloid fibers of 
all R1+X proteins and NM in the presence of 
Cu(II) was confirmed by AFM, morphologically 
similar to that formed in the absence of Cu(II) (Fig. 
S4).  By the ThT assay, Cu(II) had no obvious 
effect on the assembly of wild-type NM, but it did 
affect the lag phase of fiber formation by the 
chimeric NMs (Fig. 5).  For R1+4, the presence of 
10 equivalents of Cu(II) slightly accelerated 
assembly.  In contrast, Cu(II) showed an opposite 
effect on R1+8, reducing assembly by increasing 
the lag phase by about a factor of 2.  (This 
surprising difference in the effects of Cu(II) was 
confirmed on independent protein preparations by 
two investigators, V.G. and J.D.)  Cu(II) showed 
no effect on the lag phase of R1+8H1Q fiber 
formation. Results obtained with Thioflavin T 
fluorescence were confirmed by the SDS-
resistance assay (Fig. S5). Thus, Cu(II) must 
modulate the lag phase of R1+8 amyloid assembly 
by interacting with the histidine residues of the 
PrP repeats.  
Recombinant PrPC binds to Cu(II), Zn(II) and 
Ni(II), but has no detectable interaction with other 
metals, such as Mn(II) (55,57,58).  To test the 
specificity of Cu(II) on the R1+X proteins, we 
examined the effects of Zn(II) and Mn(II) on 
amyloid formation of R1+4 and R1+8.  Both ThT 
binding (Fig. 5) and SDS assay (Fig. S5) showed 
that, as expected from the binding selectivity, 
Mn(II) did not affect the lag phase of fiber 
formation for either protein.  Zn(II), however, 
modulated fiber formation of R1+4, R1+8 and 
R1+8H1Q with the same trend as Cu(II), 
increasing the lag phase of R1+8 amyloid 
formation, decreasing the lag phase of fiber 
formation of R1+4, and having no effect on 
R1+8H1Q.  Thus, the effects of metal ions on the 
polymerization of the R1+X proteins reflect how 
the ions rank in their selectivity of binding to 
recombinant PrPC (55,57,58).  
  
 
DISCUSSION 
 
To provide a model system for studying 
oligopeptide repeats in amyloidogenic proteins, we 
replaced the oligopeptide repeats of Sup35 with 
the well-characterized octarepeats of PrP.  The 
resulting chimeric proteins allowed us to 
characterize the properties of the PrP repeats in the 
context of both yeast prion formation and amyloid 
assembly. The chimeric proteins are fully capable 
of supporting the induction and maintenance of the 
yeast [PSI+] phenotype.  R1+4, the chimera with 
the same number of repeats as wild-type NM, 
forms amyloid fibers more rapidly than NM, 
establishing that the PrP octapeptide repeats are 
more amyloidogenic than Sup35 repeats.  
Expanding the number of PrP repeats greatly 
increases the rate of amyloid assembly in vitro and 
the spontaneous appearance of [PSI+] in vivo.  We 
previously showed that expanding the number of 
endogenous Sup35 repeats accelerates amyloid 
formation and increases the spontaneous rate of 
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[PSI+] appearance (7).  Thus, the two types of 
repeats have a very similar effect on amyloid 
conformational conversion and on yeast prion 
biology.   
Curiously, expanding the number of repeats 
destabilized the [PSI+] and [psi-] states, increasing 
switching in both directions.  Both results can be 
explained by our finding that R1+8 is more 
amyloidogenic than R1+4.  In destabilizing the 
[psi-] state, it seems most likely that R1+8 simply 
converts spontaneously into the amyloid prion 
state, [PSI+], more frequently than does R1+4.  
But how might a greater propensity to form an 
amyloid destabilize the [PSI+] state? There are a 
least two likely possibilities based on our current 
findings.  First, R1+8 amyloids may be too stable 
to be severed by Hsp104 for efficient transmission 
to daughter cells. A reduced partitioning rate 
would lead to the loss of [PSI+] (62).   Second, the 
increased efficiency of amyloid conversion might 
sequester too much of Sup35’s essential 
translation-termination activity. This would 
provide a selective advantage to cells that switch 
to the [psi-] state. A third, alternative explanation 
is that the repeats interact with Hsp104 leading to 
increased disassembly of the prion (18).  
In any case, the strong effects of repeat 
expansions are intriguing.  We previously 
proposed that [PSI+] provides a mechanism for 
cells to switch heritably between distinct 
phenotypic states (63,64).  It may be that the 
number of repeats in Sup35, and the degree of 
their amyloidogenicity, has been subject to 
evolutionary pressures to optimize switching rates 
according to the frequency of environmental 
change. 
The model substrates we have created allow 
multiple methods for interrogating the ways in 
which repeats can influence amyloid formation. 
As shown for wild-type NM, a collapsed 
oligomeric intermediate facilitates the 
intermolecular contacts required for nucleation 
(32,36,40,65).  In our chimeras, the structures 
populated by the collapsed intermediate can be 
modulated by the number of repeats, by pH and by 
metal ions, and each of these factors dramatically 
influences the lag time of unseeded polymerization.  
Thus, these substrates, together with new methods 
of single  molecule fluorescence (66), should 
provide powerful new tools to study the 
biophysics of conformational conversion, both in 
nucleation and polymerization.   
Indeed, results from the initial analysis 
reported here already have interesting implications. 
First, although wild-type NM and R1+4 have very 
different spontaneous nucleation rates they have 
virtually identical seeded polymerization rates.  
The increased amyloidogenicity of R1+4 
compared to NM, then, is solely do to a change in 
spontaneous nucleation.  Second, R1+4 and NM 
have much slower rates of seeded polymerization 
than R1+8. Third, and most strikingly, these very 
different rates of seeded polymerization are 
independent of the seed.  That is, seeds formed by 
R1+8, by R1+4, or by wild-type NM cross-seed 
polymerization of all three proteins in the very 
same way. These results fit well with one 
structural model for NM fibers, but not another. In 
the model proposed by Shewmaker et al. (67), the 
residues of the N domain stack upon each other, 
with the repeat region forming an extensive 
intermolecular interface.  Under this model, it 
would be hard to understand why replacing 38 
amino acids (out of 123) in the N domain with 64 
heterologous amino acids from the PrP protein, 
have virtually no effect on cross seeding activity.  
In the second model by Krishnan et al. (36,40), the 
repeat region is largely sequestered from 
intermolecular contacts.  The repeats are 
envisioned as coiling upon each other during 
amyloid formation, which would be consistent 
with facilitated nucleation we observe with 
expanding the repeats.  However, intermolecular 
contacts are primarily made by flanking regions in 
this model (36). Efficient cross-seeding between 
wild-type NM and the two chimeras would 
therefore be expected, since they contain the same 
sequences in the flanking regions for inter-
molecular contacts (36,40,65).   
Further study of these chimeric proteins 
might also help us understand the effects of the 
PrP repeats, pH and metal ions, on prion initiation 
by wild-type PrP. Although the repeats are outside 
the main amyloid core of PrP and lie within it in 
NM, their collapse into a compact, molten folding 
intermediate might affect PrP and NM nucleation 
in a similar way, by freeing flanking regions to 
make their critical nucleating contacts.  Acidic 
conditions facilitate the conversion of the C-
terminal segment of PrPC into aggregation-prone 
conformations (51-53), while the pH dependence 
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of full-length PrP is not well established.  Our 
chimeric proteins show decreased assembly rates 
under acidic conditions, and this effect is profound 
for proteins with repeat expansions. Such pH 
sensitivities may be of importance, in disease since 
the conversion of PrPC to PrPSc one compartment 
that might be involved in the conversion process is 
the acidic endosome (68,69).  The PrP repeats also 
interact with metal ions, especially Cu(II), which 
also has suggested roles in prion diseases (70,71).  
Although our work does not directly address how 
such Cu(II)-repeat interactions affect 
conformational conversion in full-length PrP, it 
does provide strong evidence that Cu(II) (and 
Zn(II)) can induce a major conformational 
rearrangement in the repeats that can affect 
subsequent amyloid formation.  The differential 
effect of Cu(II) ions on R1+4 vs. R1+8 may be 
due to different binding environments of Cu(II) 
upon assembly (24,56,59-61,72), although non-
assembled R1+4 and R1+8 have similar 
coordination environments indicated by the EPR 
studies. On the other hand, EPR spectrum 
broadening was observed for the soluble R1+8 
protein, suggesting a dipolar-dipolar interaction, 
which may result in a very different arrangement 
of the individual repeat units in R1+8 vs. in R1+4.  
Potentially different arrangements of the repeat 
units could result in different collapse rates and/or 
stabilities of the oligomeric intermediates.  
Interestingly, Cu(II) stimulates endocytosis of 
wild-type PrPC in human neuroblastoma cells, 
whereas such an event is compromised with 
expanding the number of the repeats (26).  Either 
deletion or expansion of the repeat region also 
interferes with Cu(II)-induced association of the 
PrP repeat region that is fused to a GST protein 
(17).  Thus, more or less than the optimal number 
of four consecutive repeats results in profound 
changes in PrP structure and function, and this 
may be one influence on the high conservation of 
repeat number during evolution.  
Efforts to understand and control the 
assembly of amyloidogenic proteins are inspired  
not only by their importance in diverse biological 
processes, but also their potential applications in 
nanotechnology (73,74).  NM fibers are stable 
under a wide variety of conditions and can 
incorporate a diversity of functions, including the 
binding of metals that allow them to form 
nanowires and electronic circuits (74).  The NM 
chimeras with PrP repeats offer new methods for 
controlling assembly with pH and metal ions, and 
further raise the possibility of adapting such 
architectures for novel materials and 
biotechnological applications.  For example, when 
the chimeras and wild-type NM are mixed 
together for assembly under different pH, different 
ratios of the chimeras and NM will be 
incorporated into individual fibers.  If a single 
cysteine mutation is presented in the chimeras, but 
not in wild-type NM, different chemical moieties 
can be introduced via the cysteine on the chimeras 
but not on wild-type NM.  As a result, controlled 
and fine-tuned patterning and mixing of chemical 
moieties covalently bound to the mixed fibers can 
be achieved.  This will significantly broaden 
functional diversity and specificity of these self-
assembly-based nanomaterials. In sum, 
modification of NM by substituting the 
endogenous repeats with those of PrP has provided 
insights on assembly that offer additional promise 
for the future.   
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FIGURE LEGENDS 
 
Fig. 1.  (A) Replacement of the Sup35 repeats with repeats from PrP.  The last four repeats of wild-
type Sup35, spanning residues 56 to 93, were replaced by the first repeat from hamster PrP and then 
various numbers of copies of the second repeat from hamster PrP.  Chimeric proteins therefore contained 
the first Sup35 repeat plus 2, 4, 5, 6, 7, and 8 PrP repeats, and so were named R1+2, R1+4, R1+5, R1+6, 
R1+7, and R1+8.  The amino acids from the Sup35 sequence are in red, and those from PrP are in black. 
(B) All of the R1+X chimeras supported both [PSI+] and [psi-] states.  The strains were spotted on YPD.   
 
Fig. 2.  Proteins form amyloid fibers with a lag phase that is eliminated by the addition of pre-
formed fiber seeds, as monitored by ThT binding. (A) In unseeded reactions, proteins with more repeats 
form amyloid fibers with a shorter lag phase.  (B) The lag phase for fiber formation is eliminated for all 
proteins by the addition of 2% (w/w) pre-formed fibers from any of the other proteins.  All reactions use 5 
μM solutions of soluble proteins of the NM domains of wild-type Sup35 (open circles), R1+4 (filled 
circles), and R1+8 (open squares).  Polymerization reactions were performed at room temperature under 
gentle rotation conditions.  ThT fluorescence intensity was normalized to the maximum intensity when 
the polymerization reaction reached an equilibrium determined by both the ThT and SDS-PAGE assays. 
  
Fig. 3.  (A) The lag times of amyloid formation for the R1+X proteins and wild-type NM showed 
different sensitivities to pH, as monitored by the ThT binding assay.  The graphs show fiber formation in 
5µM solutions of the NM domains of wild-type Sup35, R1+4, R1+8 and R1+8H1Q at room temperature 
without rotation.  The reactions were carried out at pH 2.9 (filled triangle), 3.9 (open circles), 4.9 (filled 
circles), 6.2 (open squares), and 7.2 (filled squares). (B) The propagation of amyloid fibers of the R1+X 
proteins is affected by pH, as monitored by SDS assay.  The graphs show the assay for fiber formation in 
2.5 µM solutions of the NM domains of wild-type Sup35, R1+4, R1+8 and R1+8H1Q with 2% (w/w) of 
seed from the same protein type.  The reactions were carried out at pH 2.7 (open circles), 4.5 (filled 
circles), 6.4 (open squares), and 7.7 (closed squares).  
 
Fig. 4.  EPR spectra of recombinant PrPC, R1+4, and R1+8 fully loaded with Cu(II).  R1+4 and 
R1+8 reveal binding components 1 and 2 (parallel hyperfine features labeled) indistinguishable from 
those observed for recombinant PrPC.  The recorded spectra are from monomeric protein in complex with 
Cu(II), since centrifugation to remove aggregates (after spin) did not alter the spectral features.  Samples 
were prepared in 27.5 mM NEM, 150 mM NaCl, pH 7.7.  
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Fig. 5.  Different divalent metal ions [Cu(II), Zn(II) and Mn(II)] showed different effects on the lag 
phase of amyloid formation by the wild-type NM, R1+4, R1+8 and R1+81Q, as monitored by ThT 
binding.  Metal ions were added in 10 equivalents for NM and R1+4 and in 20 equivalents for all other 
proteins.  Polymerization reactions were performed at room temperature with shaking at 600rpm.  Metal 
ion-free samples (open circle), samples containing Cu(II) (solid circle), Zn(II) (open square) and Mn(II) 
(solid triangle).  
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